Insights on the Young Investigators Forum in Neuro-Oncology - priME Oncology
Webcast
Webcast

Insights on the Young Investigators Forum in Neuro-Oncology

Building the Next Generation of Leaders in Neuro-Oncology

Not a member of My prIME? Join now for instant access.

The Young Investigators Forum in Neuro-Oncology was a two-day continuing medical education activity focused on honing the skills of fellows and junior faculty in translational and clinical research. The discussions included principles for giving presentations, updates in basic research and methodology, and recent innovations in clinical medicine for neurological tumors.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

4.75 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Sep 6, 2019

Expiration Date

Sep 6, 2020

Presentation Skills
Amy Stone, MCo

Basic Research Update in Neuro-Oncology
Frank Furnari, PhD

Clinical Update in Neuro-Oncology
Stuart Grossman, MD

Clinical Update: Evolving Clinical Trial Designs in Neuro-Oncology
Patrick Wen, MD

Mouse Models in Neuro-Oncology Research: Opportunities and Limitations
Suzanne Baker, PhD

Future Directions in Neuro-Oncology: Basic Research
Charles Stiles, PhD

Future Directions in Neuro-Oncology: Clinical Research
Fabio Iwamoto, MD

prIME Points™

Co-Chairs

  • Etty (Tika) Beneviste, PhDUniversity of Alabama School of Medicine
    Birmingham, Alabama, United States
  • David Reardon, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States

Planning Committee

  • Priscilla Brastianos, MDMGH Cancer Center
    Harvard Medical School
    Boston, Massachusetts, United States
  • Milan G. Chheda, MDWashington University School of Medicine
    St Louis, Missouri, United States
  • Eudocia Quant Lee, MD, MPHDana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts, United States
  • Monica Venere, PhDThe James Cancer Hospital and Comprehensive Cancer Center
    The Ohio State University
    Columbus, Ohio, United States

Faculty

  • Suzanne J. Baker, PhDSt Jude Children’s Research Hospital
    Memphis, Tennessee, United States
  • Maria G. Castro, PhDUniversity of Michigan Medical School
    Ann Arbor, Michigan, United States
  • Frank Furnari, PhDUniversity of California, San Diego
    San Diego, California, United States
  • Stuart Grossman, MDSidney Kimmel Cancer Center
    Johns Hopkins Medicine
    Baltimore, Maryland, United States
  • Fabio Iwamoto, MDColumbia University
    New York, New York
  • Charles D. Stiles, PhDHarvard Medical School
    Boston, Massachusetts, United States
  • Patrick Y. Wen, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States

Presentation Skills Speaker

  • Amy Stone, MCoAmy Stone Scientific and Medical Communications, Inc.
    Atlanta, Georgia, United States

The target audience for this activity includes young investigators (active fellows or junior faculty, including MDs, PhDs, and MD/PhDs) who are pursuing careers in neurologic cancers.

After successful completion of this educational activity, participants should be able to:

  • Describe skills and strategies that will aid them in their chosen academic careers
  • Assess clinical trial design, endpoints, and rationale
  • Identify effective treatment options for patients with neurologic tumors based on disease and patient characteristics
  • Evaluate recent clinical trial findings that have the potential to impact practice in the field of neurologic tumors
  • Design basic research studies based on fundamental scientific principles to address potential novel strategies in the treatment of brain tumors

This educational activity is supported by grants from AbbVie and Novocure.

Endorsed by the Society of Neuro-Oncology.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.   Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 4.75 hours

To contact Postgraduate Institute for Medicine please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Brastianos has disclosed that she has received consulting fees from Angiochem, Genentech-Roche, Lilly, and Tesaro.

Dr Butowski has disclosed that he has received contracted research fees from Amgen, BMS, Celgene, Deciphera, Ipsen, Istari, Medicenna, Oncoceutics, Rx Therapeutics, Stellar Orbus, and VBL Therapeutics.

Dr Furnari has disclosed that he has received consulting fees from Sontag Foundation.

Dr Iwamota has disclosed that he has received consulting fees from Abbvie, Merck, Northwest Biotherapeutics, Novocure, and Tocagen.

Dr Reardon has disclosed advisory/consultation fees from Abbvie; Advantagene; Amgen; Agenus; Boehringer lngelheim; Bristol­ Myers Squibb; Celldex; Deciphera; EMD Serono; FirstWord Expert Panel; Genenta Science; Genentech/Roche; Inovio; Jeffries LLC; Kiyatec; Medicenna; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; RDD Pharma; Regeneron; Stemline; Syndax Pharmaceuticals; and  Taiho Oncology, Inc. He has also disclosed that he has received research support from Acerta Phamaceuticals; Agenus;  Celldex;  EMD  Serono;  Incyte;  Inovio; Midatech; Omniox; and Tragara. He has disclosed that he has received honoraria from Abbvie; Advantagene; Agenus; Bristol-Myers Squibb; Celldex; California Institute of Regenerative Medicine; EMD Serono; Genentech/Roche; Inovio; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; Regeneron; Stemline; and Taiho Oncology, Inc. He has disclosed that he has received speaker fees from Cancer Research Institute and Institute for International Medicine (INMED).

Dr Wen has disclosed grants, research, and clinical trial support from Agios, AstraZeneca, Beigene, Eli Lilly, Immunocellular Therapeutics, Kadmon, Karyopharm, Kazia, Lilly USA, Merck, Novartis, Oncoceutic, and Vascular Biogenics. He has also disclosed participation in a speaker’s bureau for Merck. He has disclosed receipt of consulting fees from Agios Pharmaceuticals Inc, Novartis, Roche, and Taiho Oncology. He has disclosed participation on advisory boards for Abbvie, AstraZeneca, Eli Lilly, Genentech/Roche, GW Pharmaceuticals, Immunomic Therapeutics, Kadmon, Merck, Puma, Taiho Oncology, Vascular Biogenics, and Ziopharm. He also disclosed participation on data safety monitoring boards for Monteris and Tocagen.

The following have disclosed no relevant financial relationships to report:

Dr Baker
Dr Benveniste
Dr Castro
Dr Chheda
Dr Grossman
Dr Lee
Dr Stiles
Dr Stone
Dr Venere

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.